Navigation Links
Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine
Date:10/21/2011

oth Victoria and Yamagata lineages have circulated with varying prevalence, making it difficult to predict the next season's dominant lineage. Even in years when there was a good match to one B lineage strain, some influenza disease was caused by the other B lineage omitted from the vaccine. This led to the addition of a second B lineage strain in a quadrivalent formulation which may reduce influenza morbidity and mortality.

"The clinical significance of influenza B, the second most common cause of influenza-related complications and death after H3N2, is often overlooked," said Greenberg. "The results of our investigational studies to date continue to suggest that QIV has the potential to be a useful alternative to currently licensed influenza vaccines by including both B lineages that have been in circulation for the past decade. Thus, Sanofi Pasteur is continuing its clinical development program for this new vaccine which we believe will offer public health benefits." 

Study Design The study objectives included demonstration of non-inferiority of antibody responses to QIV compared with TIV, as assessed by geometric mean titer (GMT) ratios and seroconversion rates for each of the four virus strains among people age 65 years and older. Additional objectives of the study were to demonstrate superiority of antibody responses 21 days post-vaccination to each B strain in QIV compared with the TIV that does not contain the corresponding B strain, as assessed by GMT ratios and seroconversion rates among the study participants.

In the double-blind, active-controlled, multicenter study, 675 healthy people 65 years of age and older were randomized 1:1:1 to receive one intramuscular dose of 2010-2011 licensed TIV (Fluzone vaccine, containing B/Brisbane/60/2008) [Victoria lineage]), investigational TIV (containing B/Florida/04/2006) [Yamagata lineage]) or QIV (containing both B strains). All three vaccines contained the same
'/>"/>

SOURCE Sanofi Pasteur
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
2. Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
3. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
4. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
5. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
6. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
7. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
8. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
9. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
10. Sanofi-aventis Stands Behind the Safety of Lantus(R)
11. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Conn. , July 29, 2014 Numotion,s Board ... Mike Swinford will be the company,s new Chief ... highly successful 22-year career at GE where he worked primarily ... in annual revenue to over $5 billion. His most recent ... Services. "I am thrilled to join Numotion," ...
(Date:7/29/2014)... July 29, 2014 McGraw-Hill Education Professional, a ... science, technical, and medical communities, has announced the launch ... mobile application of the world-renowned medical education platform. ... AccessMedicine App , available for download onto all iOS ... able to gain access to valuable AccessMedicine ...
(Date:7/29/2014)... DIEGO , July 29, 2014  Neurocrine Biosciences, ... the Company will report its second quarter 2014 financial ... 6, 2014.  Neurocrine will then host a live conference ... provide a Company update Thursday morning, August 7, 2014 ... Participants can access the live conference call ...
Breaking Medicine Technology:Numotion Names Mike Swinford CEO 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2
... on the short arm of chromosome 6 (6p21.3), is a ... region is the human equivalent of the Major Histocompatibility Complex ... serve as the backbone of antigen presentation. The Class ... T-cells, are expressed by genes located in the HLA-A, -B ...
... the level of blood oxygenation can be an ... levels in the clinical setting is often desirable. ... sophisticated technology into easily used point-of-care devices, recent ... hemoglobin values., ,HemoCue, Inc., Lake Forest, Calif., says ...
Cached Medicine Technology:The Past, Present and Future of HLA Typing 2The Past, Present and Future of HLA Typing 3Hemoglobin Testing at the Point of Care 2Hemoglobin Testing at the Point of Care 3
(Date:7/29/2014)... 29, 2014 (HealthDay News) -- Decorative contact lenses may ... careful, they can cause serious eye damage. Decorative ... ophthalmologist, according to the U.S. Food and Drug Administration ... a valid prescription for these lenses and buy them ... spread the word about the potential health risks associated ...
(Date:7/29/2014)... Penn State College of Medicine, have jointly received ... health data research network., The Patient-Centered Outcomes Research ... Protection and Affordable Care Act, awarded the funds ... and Johns Hopkins University -- and each of ... come together to create a Clinical Data Research ...
(Date:7/29/2014)... July 29, 2014 July 29, 2014 – ... care, is proud to announce that it is a Bronze ... online video segments; Silverado Through a Child's Eye ... , In Silverado Through a Child's Eye , seven-year-old ... mom at Silverado Beverly Place, a memory care community in ...
(Date:7/29/2014)... BC (PRWEB) July 29, 2014 According ... http://www.idataresearch.com ), the leading global authority in medical device ... will grow to over $8 billion by ... advancement, particularly in the transcatheter heart valve market, which ... (THVI) and the transcatheter mitral valve repair (TMVR) segments. ...
(Date:7/29/2014)... WA (PRWEB) July 29, 2014 According ... marijuana in both the recreational and the medicinal sectors ... As legalized marijuana becomes more accepted in mainstream culture, ... drug aside from the traditional and more dangerous forms ... products are becoming quite the trend in legalized states ...
Breaking Medicine News(10 mins):Health News:It's 'Buyer Beware' for Decorative Contact Lenses, FDA Says 2Health News:New network unites university health care research 2Health News:Silverado Selected a Winner in the 35th Annual Telly Awards for Producing Inspiring Online Video Content 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 3Health News:Marijuana Edibles Sales Show Growth in Market 2
... PARK, Fla., May 18 Transitions Optical, Inc.,today announced ... relevant information about eye health issues through SMS text ... have the option to subscribe to,receive valuable advice and ... eyes to see better today and in the future. ...
... Washinton DC (18 May 2009) Research published this week ... the annual costs of autism spectrum disorder (ASD) to be ... children with ASDs were estimated to be 2.7 billion per ... be presented at the Autism & Employment Workshop taking place ...
... MEI,s Broad Solution Offerings CORAL SPRINGS, Fla., May ... of The MEI Healthcare Group, announced today a ... GE ), a leading provider of healthcare technology. ... customers the option of MEI,s broad solutions, including ...
... by Shire to Patients Taking Lialda(R) (mesalamine) or Pentasa(R) ... Lost Their Jobs in 2009PHILADELPHIA, May 18 Shire ... global specialty biopharmaceutical company, is responding to the needs ... and prescribed gastrointestinal (GI) medications from Shire by expanding ...
... season; experts less sure about global outlook , , MONDAY, May ... raising critical questions about the timing of bringing a new ... the people who need it. , If vaccine manufacturers shift ... seasonal influenza vaccine, experts say. If they wait too long, ...
... blast injuries have become the signature injuries. These can ... damage to the visual system and the visual processing centers ... with them." Gregory Goodrich, Ph.D., Veterans, Administration Research Psychologist, on ... N.Y., May 18 The journey home is a bittersweet ...
Cached Medicine News:Health News:SMS Technology Places Eye Health Educational Information at Hispanics' Fingertips 2Health News:Autism in the UK costs more than $41 billion every year, shows new research 2Health News:Autism in the UK costs more than $41 billion every year, shows new research 3Health News:MEI Development Corporation and GE Healthcare Sign Strategic Agreement 2Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 2Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 3Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 4Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 5Health News:Adequate Supply of Swine Flu Vaccine Uncertain 2Health News:Adequate Supply of Swine Flu Vaccine Uncertain 3Health News:Becoming Aware of Veterans' Vision Needs 2
Multi-constituent normal and abnormal plasma controls for routine and specialty assays performed on the STA© family of hemostasis analyzers....
PT, PTT, Fibrinogetn & TT Normal and Abnormal Controls...
Fructosamine Calibrator...
ApolipoproteinA-1 & B Calibrator...
Medicine Products: